GIST

IDRx Appoints David P. Kerstein, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, March 27, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Sumitomo Pharma, Takeda Pharmaceutical Company, Tufts University, Patient, Therapy, Takeda, GIST, ARIAD Pharmaceuticals, Pharmaceutical industry

IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced the appointment of David P. Kerstein, M.D., as Chief Medical Officer.

Key Points: 
  • IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced the appointment of David P. Kerstein, M.D., as Chief Medical Officer.
  • Dr. Kerstein brings to IDRx deep experience in early- and late-stage oncology drug development, including multiple precision oncology medicines.
  • He joins the founding IDRx R&D leadership team of Jessica Christo, Chief Development Operations Officer, and Vivek (Vic) Kadambi, Ph.D., Chief Product Development Officer.
  • Before Theseus, Dr. Kerstein served as Chief Medical Officer of Anchiano Therapeutics Ltd.

IDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBO

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Cantor Fitzgerald, Ohio State University, Development, J. P. Morgan, Information technology, Novo Nordisk, NSCLC, Genentech, University, Brad, Patient, Research, Sale, Acquisition, Lung cancer, Research and development, Therapy, Takeda, GIST, ARIAD Pharmaceuticals, RBC Capital Markets, Forma, Drug resistance, Pharmaceutical industry

Ben Auspitz, IDRx’s co-founder and founding CEO, and also co-founder of Forge Life Science Partners, will become Chairman of the IDRx Board of Directors.

Key Points: 
  • Ben Auspitz, IDRx’s co-founder and founding CEO, and also co-founder of Forge Life Science Partners, will become Chairman of the IDRx Board of Directors.
  • He played a key role in the company's evolution from early research to a global commercial oncology company, and its subsequent acquisition by Takeda.
  • He led Selecta through several significant financing and strategic transactions, including a $730 million licensing agreement for its lead program.
  • “I look forward to working with Tim, Ben, and the team at IDRx to grow the Company with the backbone of IDRX-42,” said Mr. Dahms.

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Research, Glioblastoma, Patient, GBM, Tumor microenvironment, University, Spacecraft, Abstract (summary), Biology, Mesothelioma, AACR, PDX, Cancer, University of Copenhagen, Poster, Finsen Laboratory, GIST, ADC, Invasion, Receptor (biochemistry), Associate professor

The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.

Key Points: 
  • The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.
  • uPARAP is a novel ADC target overexpressed by mesenchymal cancer cells including soft tissue and bone sarcomas, GIST as well as mesothelioma and glioblastoma, and has the potential to play a key role in modulating the tumor microenvironment.
  • The data demonstrate that uPARAP is strongly over-expressed in glioblastoma cells and that a uPARAP targeting ADC exhibits strong in vivo anti-tumor activity in a glioblastoma PDX model.
  • We are extremely encouraged by the data highlighted in this study, which provides further evidence on the potential effectiveness of uPARAP as a novel target for ADCs in glioblastoma multiforme.

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Research, Glioblastoma, Patient, GBM, Tumor microenvironment, University, Spacecraft, Abstract (summary), Biology, Mesothelioma, AACR, PDX, Cancer, University of Copenhagen, Poster, Finsen Laboratory, GIST, ADC, Invasion, Receptor (biochemistry), Associate professor

The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.

Key Points: 
  • The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.
  • uPARAP is a novel ADC target overexpressed by mesenchymal cancer cells including soft tissue and bone sarcomas, GIST as well as mesothelioma and glioblastoma, and has the potential to play a key role in modulating the tumor microenvironment.
  • The data demonstrate that uPARAP is strongly over-expressed in glioblastoma cells and that a uPARAP targeting ADC exhibits strong in vivo anti-tumor activity in a glioblastoma PDX model.
  • We are extremely encouraged by the data highlighted in this study, which provides further evidence on the potential effectiveness of uPARAP as a novel target for ADCs in glioblastoma multiforme.

Connell Funeral Home Leverages Careopolis to Enhance Healing, Togetherness and Quality of Life

Retrieved on: 
Tuesday, April 2, 2024
Friends, Growth, Memory, Empathy, Metropolis, Ache, Death, GIST, Family, Ageing

This agreement provides clients, families and the community access to CareFlash's signature platform, "The Careopolis, a Metropolis of Love and Empathy."

Key Points: 
  • This agreement provides clients, families and the community access to CareFlash's signature platform, "The Careopolis, a Metropolis of Love and Empathy."
  • As in the brief video on Connell's website ( https://www.connellfuneral.com/careopolis/careopolis ), a Careopolis is an online "caring community," created and operated by a family and invited loved ones.
  • A Careopolis enhances how loved ones:
    Adds Jamie Connell, Co-President, Connell Funeral Home, "When families experience a death, loved ones can at times be at a loss for what to say.
  • Adds Matt Connell, Co-President, Connell Funeral Home, "Forward thinking death-care professionals view our role more holistically than has traditionally been the case.

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, February 26, 2024
HER2, PFS, AAAAI, KIT, Research, Completeness, TSS, ASCO, ASH, WT, Cash, Part, Safety, PEAK, AACR, Cogent, Conference, GIST, Society, PPR, Patient, The, PIPE, FGFR2, Clinical trial, Poster, G&A, Sunitinib, Initiate, IND, Brain, TKI, APEX, Cancer, American Academy, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2023.

Key Points: 
  • and BOULDER, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2023.
  • SUMMIT is a registration-directed, randomized, double-blind, placebo-controlled, global, multicenter, clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM).
  • Cash and Cash Equivalents: As of December 31, 2023, Cogent had cash, cash equivalents and marketable securities of $273.2 million.
  • During the quarter Cogent also completed and paid for bulk manufacturing campaigns of bezuclastinib to continue supporting the company’s clinical trials.

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Retrieved on: 
Thursday, February 22, 2024
Poster, AAAAI, PD, KIT, Week, TSS, ISM, Safety, Quality of life, News, SSM, Overalls, Edema, Cogent, GIST, Deficit spending, Webcast, Mast cell, Patient, SAE, 1B, APEX, American Academy, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported positive Part 1b data from the Company’s ongoing SUMMIT trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM) at the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) meeting taking place February 23-26, 2024 in Washington, D.C.

Key Points: 
  • “The magnitude and speed of symptomatic reductions, along with corresponding improvements in quality-of-life, reported by patients in SUMMIT Part 1b has not been seen previously with other treatment options in this patient population.
  • Thirty-four patients in Part 1b were treated with either bezuclastinib or placebo plus best supportive care.
  • Patients were enrolled with the following sub-types: 33 patients with indolent systemic mastocytosis (ISM) and one patient with smoldering systemic mastocytosis (SSM).
  • Thirty-four patients enrolled in SUMMIT Part 1b were evaluated for signs of clinical activity over 12 weeks, including well-accepted biomarkers of disease burden.

Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Pharmaceutical, Health, Oncology, OS, KIT, European, Investigational New Drug, Trial of the century, DNA, Research, Patient, IND, Autophagy, ASCO, GIST, Public expenditure, FDA, EMA, MAA, Part, Food, Society, TGCT, Gastrointestinal stromal tumor, European Medicines Agency, Sunitinib, Neoplasm, Cancer, INSIGHT, Tenosynovial giant cell tumor, NDA, Nature Medicine, Pharmaceutical industry

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.
  • Expects to present updated results from the Phase 1/2 study of vimseltinib in TGCT in the second half of 2024.
  • Expects to initiate a Phase 2 proof-of-concept study of vimseltinib for the treatment of chronic graft versus host disease (cGVHD) in the fourth quarter of 2024.
  • Cost of Sales: Cost of sales were $1.8 million in the fourth quarter of 2023, which includes $0.9 million in cost of product sales, compared to cost of product sales of $0.7 million for the fourth quarter of 2022.

GIST Researchers Showcase New Breakthroughs for Unlocking the Potential of Plasmonics

Retrieved on: 
Wednesday, January 31, 2024
Advanced Optical Materials, Nanostructure, Magnesium, Research, Orientation, Sunlight, Nanoparticle, Environment, Light, GIST, Human body, Skin, Personal computer, Doctor of Philosophy, Optical phenomena, Assistant, Wound healing, Rotation, Advanced Materials, Seed

In this regard, "shadow growth" is a technique that utilizes vacuum deposition to produce nanoparticles from a wide range of 2D and 3D shapes in nanoscale.

Key Points: 
  • In this regard, "shadow growth" is a technique that utilizes vacuum deposition to produce nanoparticles from a wide range of 2D and 3D shapes in nanoscale.
  • Recent research progress in controlling this shadow effect has broadened the possibilities for the creation of different nanostructures.
  • This formation depends on the size of the seed, spacing between the seeds, and the inclination of the substrate."
  • These structures exhibit tunable optical properties achieved through suitable modifications to their material, shape, and surrounding environment.

Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Retrieved on: 
Thursday, January 18, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Patient, Progression-free survival, KIT, Neoplasm, OS, Hypertension, ASCO, Fatigue, Society, Cancer, Myalgia, Survival rate, Public health, INSIGHT, AP, PFS, Safety, Diarrhea, GIST, Sunitinib, Nature Medicine, Preventive healthcare, Pharmaceutical industry

There were fewer patients with Grade 3/4 drug-related treatment emergent adverse events (TEAE) with QINLOCK (26.5%) compared with sunitinib (55.2%).

Key Points: 
  • There were fewer patients with Grade 3/4 drug-related treatment emergent adverse events (TEAE) with QINLOCK (26.5%) compared with sunitinib (55.2%).
  • Dose interruptions and reductions as well as treatment discontinuations due to TEAEs were lower with QINLOCK versus sunitinib.
  • Patients with mutations in KIT exon 11 and 17/18 had improved progression-free survival, objective response rate, and overall survival with QINLOCK versus sunitinib.
  • Based on the results of this prespecified exploratory objective in INTRIGUE, the Company is enrolling the INSIGHT pivotal Phase 3 clinical study of QINLOCK in second-line GIST patients with mutations in KIT exon 11 and 17/18 only.